[시장보고서]저분자 헬스케어 수탁제조 시장 규모, 점유율 및 동향 분석 리포트 : 서비스별, 치료 영역별, 지역별, 부문 예측(2025-2033년)

저분자 헬스케어 수탁제조 시장 규모, 점유율 및 동향 분석 리포트 : 서비스별, 치료 영역별, 지역별, 부문 예측(2025-2033년)

Small Molecule Healthcare Contract Manufacturing Market Size, Share & Trends Analysis Report By Service (API, Finished Drug Product), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1888646

리서치사 : Grand View Research

발행일 : 2025년 11월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,701,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,164,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,089,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

저분자 헬스케어 수탁제조 시장 요약

세계의 저분자 헬스케어 수탁제조 시장 규모는 2024년에 1,090억 4,000만 달러로 추정되며, 2033년까지 3,106억 달러에 달할 것으로 예측됩니다.

2025-2033년 연평균 12.56%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 시장 성장의 주요 요인으로는 비용 효율적인 의약품 생산에 대한 수요 증가, 저분자 치료제 파이프라인 확대, 연구개발 및 상업화 등 핵심 업무에 집중하기 위한 제약사의 제조 아웃소싱 증가 등을 꼽을 수 있습니다.

또한 제약사들이 운영 비용 절감, 유연성 향상, 시장 출시 기간 단축을 위해 제조 활동의 아웃소싱을 늘리고 있는 것도 시장을 촉진하고 있습니다. 신규 저분자 의약품의 개발 및 상업화에는 막대한 자본 투자와 전문 인프라가 필요하므로 기업은 생산 효율화를 위해 수탁제조기관(CMO)에 의존하고 있습니다. 제네릭 및 브랜드 저분자 의약품에 대한 수요 증가와 더불어 암, 심혈관 질환, 당뇨병과 같은 만성질환 치료제 파이프라인의 확대로 인해 확장 가능한 고품질 제조 서비스의 필요성이 더욱 커지고 있습니다.

또한 공정 화학, 분석 방법, 연속 생산의 기술 발전은 저분자 의약품 생산의 생산 효율과 수율을 더욱 향상시키고 있습니다. 고활성 원료의약품(HPAPI)과 복잡한 제형에 대한 관심이 높아지면서 제약사들은 첨단 봉쇄 기술과 규제 대응 능력을 갖춘 전문 CDMO와의 제휴를 추진하고 있습니다.

세계의 저분자 헬스케어 수탁제조 시장에서 치료 영역별 변동 분석
세계의 저분자 헬스케어 수탁제조 시장 규모와 동향 분석(치료 영역별, 2021-2033년)
종양학
심혈관 질환
신경질환
감염증
정형외과 질환
대사성 질환
자가면역질환
소화기 질환
호흡기질환
안과
치과 질환
기타

제6장 저분자 헬스케어 수탁제조 시장 : 최종 용도별 추정·동향 분석

세계의 저분자 헬스케어 수탁제조 시장에서 최종 용도별 변동 분석
세계의 저분자 헬스케어 수탁제조 시장 규모 및 동향 분석(최종 용도별, 2021-2033년)
제약회사
바이오테크놀러지 기업
기타

제7장 저분자 헬스케어 수탁제조 시장 : 서비스별, 용도별 추정·동향 분석

지역별 시장 대시보드
세계 지역별 시장 개요
시장 규모, 예측, 동향 분석(2021-2033년) :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
- 오만
- 카타르

제8장 경쟁 구도

기업 분류
- 시장 리더
- 신규 기업
저분자 헬스케어 수탁제조 시장 현황 분석, 2024년
기업 개요
- Lonza Group
- Catalent Inc.
- Recipharm AB
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- Cambrex Corporation
- Eurofins Scientific
- Siegfried Holding AG
- CordenPharma
- PCI Pharma Services

KSA

영문 목차

영문목차

Small Molecule Healthcare Contract Manufacturing Market Summary

The global small molecule healthcare contract manufacturing market size was estimated at USD 109.04 billion in 2024 and is projected to reach USD 310.6 billion by 2033, growing at a CAGR of 12.56% from 2025 to 2033. The market growth is driven by the increasing demand for cost-efficient drug production, the expanding pipeline of small molecule therapeutics, and the rising trend of outsourcing among pharmaceutical companies to focus on core competencies such as R&D and commercialization.

In addition, the market is driven by the rising outsourcing of manufacturing activities by pharmaceutical companies seeking to reduce operational costs, enhance flexibility, and accelerate time-to-market. Developing and commercializing new small-molecule drugs requires significant capital investment and specialized infrastructure, prompting companies to rely on contract manufacturing organizations (CMOs) for production efficiency. The increasing demand for generic and branded small molecule drugs, coupled with the expanding pipeline of therapeutics targeting chronic diseases such as cancer, cardiovascular disorders, and diabetes, is further boosting the need for scalable, high-quality manufacturing services.

Furthermore, technological advancements in process chemistry, analytical methods, and continuous manufacturing are further enhancing production efficiency and yield in small molecule manufacturing. The growing focus on high-potency active pharmaceutical ingredients (HPAPIs) and complex formulations has also encouraged pharmaceutical companies to partner with specialized CDMOs that possess advanced containment and regulatory capabilities.

Global Small Molecule Healthcare Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule healthcare contract manufacturing market report based on phase, service, therapeutic area, end use, and region:

Service Outlook (Revenue, USD Million, 2021 - 2033)
API
Development & Scale-up Services
Finished dose formulations
Packaging
Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Cardiovascular Disease
Neurological Disorders
Infectious Diseases
Orthopedic Diseases
Metabolic Disorders
Autoimmune Diseases
Gastrointestinal Disorders
Respiratory Diseases
Ophthalmology
Dental Diseases
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical Companies
Biotechnology Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights

Chapter 3. Small Molecule Healthcare Contract Manufacturing Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Small Molecule Healthcare Contract Manufacturing Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunities
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Supply Chain Analysis
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Small Molecule Healthcare Contract Manufacturing Market: Service Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Small Molecule Healthcare Contract Manufacturing Market Service Movement Analysis
4.3. Global Small Molecule Healthcare Contract Manufacturing Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
4.4. Active Pharmaceutical Ingredient (API)
- 4.4.1. Active Pharmaceutical Ingredient (API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Development & Scale-up Services
- 4.5.1. Development & Scale-up Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Finished dose formulations
- 4.6.1. Finished dose formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Packaging
- 4.7.1. Packaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Small Molecule Healthcare Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Small Molecule Healthcare Contract Manufacturing Market Therapeutic Area Movement Analysis
5.3. Global Small Molecule Healthcare Contract Manufacturing Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
5.4. Oncology
- 5.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Cardiovascular Disease
- 5.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Neurological Disorders
- 5.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Infectious Diseases
- 5.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Orthopedic Diseases
- 5.8.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Metabolic Disorders
- 5.9.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Autoimmune Diseases
- 5.10.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Gastrointestinal Disorders
- 5.11.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12. Respiratory Diseases
- 5.12.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.13. Ophthalmology
- 5.13.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.14. Dental Diseases
- 5.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.15. Others
- 5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule Healthcare Contract Manufacturing Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Small Molecule Healthcare Contract Manufacturing Market End Use Movement Analysis
6.3. Global Small Molecule Healthcare Contract Manufacturing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical Companies
- 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Biotechnology Companies
- 6.5.1. Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule Healthcare Contract Manufacturing Market: Regional Estimates & Trend Analysis by Service, Service, End Use

7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Competitive Scenario
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Competitive Scenario
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Competitive Scenario
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Competitive Scenario
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Competitive Scenario
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Competitive Scenario
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East & Africa
- 7.8.1. Middle East & Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Competitive Scenario
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Competitive Scenario
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Competitive Scenario
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Competitive Scenario
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.6. Oman
  - 7.8.6.1. Key Country Dynamics
  - 7.8.6.2. Competitive Scenario
  - 7.8.6.3. Regulatory Framework
  - 7.8.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.7. Qatar
  - 7.8.7.1. Key Country Dynamics
  - 7.8.7.2. Competitive Scenario
  - 7.8.7.3. Regulatory Framework
  - 7.8.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
8.2. Small Molecule Healthcare Contract Manufacturing Market Position Analysis, 2024
8.3. Company Profiles
- 8.3.1. Lonza Group
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Financial Performance
  - 8.3.1.3. Service Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. Catalent Inc.
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Financial Performance
  - 8.3.2.3. Service Benchmarking
  - 8.3.2.4. Strategic Initiatives
- 8.3.3. Recipharm AB
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Financial Performance
  - 8.3.3.3. Service Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. Thermo Fisher Scientific Inc.
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Financial Performance
  - 8.3.4.3. Service Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. WuXi AppTec
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Financial Performance
  - 8.3.5.3. Service Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Cambrex Corporation
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Financial Performance
  - 8.3.6.3. Service Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. Eurofins Scientific
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Financial Performance
  - 8.3.7.3. Service Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. Siegfried Holding AG
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Financial Performance
  - 8.3.8.3. Service Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. CordenPharma
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Financial Performance
  - 8.3.9.3. Service Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. PCI Pharma Services
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Financial Performance
  - 8.3.10.3. Service Benchmarking
  - 8.3.10.4. Strategic Initiatives